Author/Authors :
Bakhtiary, Mehrdad tehran university of medical sciences tums - Cellular and Molecular Research Center, تهران, ايران , Bakhtiary, Mehrdad tehran university of medical sciences tums - Department of Anatomy, تهران, ايران , Marzban, Mohsen tehran university of medical sciences tums - Department of Anatomy, تهران, ايران , Mehdizadeh, Mehdi tehran university of medical sciences tums - Cellular and Molecular Research Center, تهران, ايران , Mehdizadeh, Mehdi tehran university of medical sciences tums - Department of Anatomy, تهران, ايران , Joghataei, Mohammad Taghi tehran university of medical sciences tums - Cellular and Molecular Research Center, تهران, ايران , Joghataei, Mohammad Taghi tehran university of medical sciences tums - Department of Anatomy, تهران, ايران , Khoei, Samideh tehran university of medical sciences tums - Department of Medical Physics, تهران, ايران , Pirhajati Mahabadi, Vahid tehran university of medical sciences tums - Cellular and Molecular Research Center, تهران, ايران , Laribi, Bahareh tehran university of medical sciences tums - Department of Immunology, تهران, ايران , Tondar, Mahdi tehran university of medical sciences tums - Department of Anatomy, تهران, ايران , Moshkforoush, Arash sharif university of technology - Department of Materials Science and Engineering, تهران, ايران
Abstract :
Background: Recent clinical studies of treating traumatic brain injury (TBI) with autologous adult stem cells led us to compare effect of intravenous injection of bone marrow mesenchymal stem cells (BMSC) and bone marrow hematopoietic stem cell mobilization, induced by granulocyte colony stimulating factor (G-CSF), in rats with a cortical compact device. Methods: Forty adult male Wistar rats were injured with controlled cortical impact device and divided randomly into four groups. The treatment groups were injected with 2 x 10^6 intravenous bone marrow stromal stem cell (n = 10) and also with subcutaneous G-CSF (n = 10) and sham-operation group (n = 10) received PBS and bromodeoxyuridine (Brdu) alone, i.p. All injections were performed 1 day after injury into the tail veins of rats. All cells were labeled with Brdu before injection into the tail veins of rats. Functional neurological evaluation of animals was performed before and after injury using modified neurological severity scores (mNSS). Animals were sacrificed 42 days after TBI and brain sections were stained by Brdu immunohistochemistry. Results: Statistically, significant improvement in functional outcome was observed in treatment groups compared with control group (P 0.01). mNSS showed no significant difference between the BMSC and G-CSF-treated groups during the study period (end of the trial). Histological analyses showed that Brdu-labeled (MSC) were present in the lesion boundary zone at 42nd day in all injected animals. Conclusion: In our study, we found that administration of a bone marrowstimulating factor (G-CSF) and BMSC in a TBI model provides functional benefits.
